Evidence map›Paper›PMID 39158599›Full record

ArticleClinical research in cardiology : official journal of the German Cardiac Society2025

Favorable safety profile of NOAC therapy in patients after tricuspid transcatheter edge-to-edge repair.

Isabel A Hoerbrand, Martin J Kraus, Martin Gruber, Nicolas A Geis, Philipp Schlegel, Norbert Frey, Mathias H Konstandin

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical research in cardiology : official journal of the German Cardiac Society, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Isabel A HoerbrandDepartment of Internal Medicine III, Division of Cardiology, University Hospital Heidelberg, Ruprecht-Karls University Heidelberg, Im Neuenheimer Feld 410, 69120, Heidelberg, Germany.
Martin J KrausDepartment of Internal Medicine III, Division of Cardiology, University Hospital Heidelberg, Ruprecht-Karls University Heidelberg, Im Neuenheimer Feld 410, 69120, Heidelberg, Germany.
Martin GruberDepartment of Internal Medicine III, Division of Cardiology, University Hospital Heidelberg, Ruprecht-Karls University Heidelberg, Im Neuenheimer Feld 410, 69120, Heidelberg, Germany.
Nicolas A GeisDepartment of Internal Medicine III, Division of Cardiology, University Hospital Heidelberg, Ruprecht-Karls University Heidelberg, Im Neuenheimer Feld 410, 69120, Heidelberg, Germany.
Philipp SchlegelDepartment of Internal Medicine III, Division of Cardiology, University Hospital Heidelberg, Ruprecht-Karls University Heidelberg, Im Neuenheimer Feld 410, 69120, Heidelberg, Germany.
Norbert FreyDepartment of Internal Medicine III, Division of Cardiology, University Hospital Heidelberg, Ruprecht-Karls University Heidelberg, Im Neuenheimer Feld 410, 69120, Heidelberg, Germany.
Mathias H KonstandinDepartment of Internal Medicine III, Division of Cardiology, University Hospital Heidelberg, Ruprecht-Karls University Heidelberg, Im Neuenheimer Feld 410, 69120, Heidelberg, Germany. mathias.konstandin@med.uni-heidelberg.de.ORCID http://orcid.org/0000-0001-9852-1039

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundTranscatheter edge-to-edge repair for severe tricuspid regurgitation (TR) is a new treatment option (t-TEER). Data on optimal antithrombotic therapy after t-TEER in patients with an indication for anticoagulation are scarce and evidence-based guideline recommendations are lacking. We sought to investigate efficacy and safety of novel oral anticoagulation (NOAC) and vitamin-K-antagonists (VKA) in patients undergoing t-TEER.

methodsAmong 78 consecutive patients with t-TEER of severe TR, 69 patients were identified with concomitant indication for oral anticoagulation. Outcomes of these patients treated with NOAC or VKA were compared over a median follow-up period of 327 (177-460) days.

resultsDespite elevated thromboembolic and bleeding risk scores (CHA

conclusionResults of this study indicate that NOACs may offer a favorable risk-benefit profile for patients with concomitant indication for anticoagulation therapy following t-TEER.

Indexed as

AnticoagulantsCardiac CatheterizationThromboembolismTricuspid Valve InsufficiencyAdministration, OralAgedAged, 80 and overFactor Xa InhibitorsFemaleFollow-Up StudiesHemorrhageHumansMalePyrazolesPyridonesRetrospective StudiesAnticoagulantsapixabanFactor Xa InhibitorsPyrazolesPyridonesRivaroxabanVitamin KBleedingNOACOral anticoagulationTranscatheter edge-to-edge repairTranscatheter tricuspid valve repairTricuspid diseaseTricuspid regurgitation

Identifiers

PMID39158599
PMCPMC12202579

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.